Noonan/Russo Communications keeps a low profile, but it is a high-flier in one of the most dramatic sectors of the public relations business: biotechnology. On track for revenues of around $15 million this year, Noonan/Russo now ranks among the top 10 independent PR firms in the country, and among the leaders in healthcare and investor relations. And with advances in the volatile biotech arena coming at a faster pace than ever, thanks to the mapping of the human genome, Noonan/Russo is poised for even more spectacular growth.
Noonan/Russo offers a broad array of healthcare communications services, including media and investor relations, brand marketing and positioning, managed care consulting, and a recently established interactive services division that includes web site development and a host of online communications products. The firm’s clients include leaders in the biotech field such as Advanced Cell Technology, Lion Bioscience and Serono, and new additions this year include Rosetta Inpharmatics, Tecan, and Nutri Pharma. For Serono, Europe’s largest (and the world’s third largest) biotech company, Noonan/Russo teams in the U.S. and in its London satellite office are handling a wide range of media and investor relations projects, positioning the client for its listing on the NYSE and increasing exposure in the international press. For Advanced Cell Technology, a leader in the cloning field, the firm has handled publicity around the company’s cloning research on cows, making front-page headlines around the world.
Noonan/Russo has also taken steps to expand its leadership team over the past 12 months, adding Stephen Grendel, former healthcare correspondent for CNBC, as vice president of corporate communications; Douglas Trigg, former senior vp of marketing at Medic Alert, as head of its San Francisco office; and Miriam Weber, formerly of Burns McClellan, as vp of financial communications.